Growth differentiation factor-15 and preparation method thereof
Through HEK293 cell expression system and affinity chromatography, the problem of functional deletion and limited yield of the prokaryotic expression system in the expression of growth differentiation factor-15 was solved, and high purity and high biological activity protein preparation was achieved, which improved research and clinical application feasibility.
Patent Information
- Application Number
- CN202411475286.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-22
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing prokaryotic expression systems have problems of loss of function, insufficient modification and limited yield when expressing complex proteins such as growth differentiation factor-15, making it difficult to provide high-purity and high biological activity proteins, which affects the feasibility of research and clinical applications.
Using the HEK293 cell expression system, nucleic acids were transfected into HEK293 cells by constructing recombinant expression vectors and using PEI transfection reagents, and in vitro culture and purification were carried out in vitro to ensure the correct glycosylation, phosphorylation and other modifications of proteins. , improve expression and purity.
Achieving growth differentiation factor-15 with high purity (over 95%) and high expression (190mg/L) in a short period of time ensures the biological activity and stability of the protein and provides a more reliable research and clinical application basis.
Smart Images

Figure CN118995820A_ABST
Abstract
Description
Technical Field
[0001] The present invention specifically relates to a growth differentiation factor-15 and a preparation method thereof, and belongs to the technical field of molecular biology. Background Art
[0002] Growth differentiation factor-15 is a multifunctional protein factor that belongs to the transforming growth factor-β superfamily. It is expressed in a variety of tissues and cell types. Its expression level is regulated by a variety of physiological and pathological factors. It has been widely studied and has demonstrated important biological functions and clinical application potential in many fields.
[0003] At present, the technical fields involved in growth differentiation factor-15 include tumor biology, cardiovascular disease, metabolic disease, inflammation and immune regulation, regenerative medicine and tissue engineering. Growth differentiation factor-15 is in urgent need of large-scale expression for application in research and clinical practice. Due to its potential application value in a variety of diseases, large-scale expression and purification of growth differentiation factor-15 is crucial for in-depth study of its mechanism of action and development of treatment methods. Growth differentiation factor-15 on the market is mostly expressed using the Escherichia coli prokaryotic expression system. The advantage of prokaryotic expression is that the gene expression product can be obtained in a short time, the cost is relatively low, and the method is relatively simple. However, the prokaryotic expression system has some significant disadvantages when expressing complex proteins such as growth differentiation factor-15. First, prokaryotic cells lack complex post-translational modification mechanisms and cannot effectively ensure the correct folding and modification of proteins, which may lead to functional loss. Secondly, the post-translational modification process of prokaryotic cells is relatively simple, and it is impossible to achieve the correct glycosylation, phosphorylation and other modifications required for growth differentiation factor-15 protein, which is crucial for its biological activity and stability. Finally, prokaryotic expression systems usually have limited production and are unable to provide large amounts of growth differentiation factor-15, thus affecting the feasibility of related research and applications.
[0004] Therefore, there is an urgent need for a method to express growth differentiation factor-15 protein instead of the prokaryotic expression system to obtain a protein with better functionality and higher stability, providing a more reliable basis for related research and applications. Summary of the invention
[0005] In order to overcome the existing deficiencies, the present invention provides a growth differentiation factor-15 and a preparation method thereof, which improves the purity and expression level of growth differentiation factor-15.
[0006] In order to achieve the above object, the technical solution adopted by the present invention is: In a first aspect, the present invention provides a method for preparing growth differentiation factor-15, comprising: A nucleic acid for preparing growth differentiation factor-15 is constructed, the nucleotide sequence of which is shown in SEQ ID NO:5; Connecting the nucleic acid to an expression vector by enzyme digestion to obtain a recombinant expression vector; HEK293 cells were transfected with the recombinant expression vector to obtain recombinant cells; The recombinant cells are cultured in vitro, the culture supernatant is collected by centrifugation, and then separated and purified to obtain the recombinantly expressed growth differentiation factor-15.
[0007] In combination with the first aspect, further, the amino acid sequence encoded by the nucleic acid is shown in SEQ ID NO:4.
[0008] Furthermore, the nucleic acid is connected to an expression vector via two restriction sites, NheⅠ and HindⅢ, to obtain a recombinant expression vector.
[0009] Furthermore, the promoter used in the expression vector is any one of CMV promoter, SV40 promoter or T7 promoter.
[0010] Furthermore, the expression vector is pcDNA3.1(+).
[0011] Furthermore, using the recombinant expression vector to transfect HEK293 cells includes: mixing the recombinant expression vector with a PEI transfection reagent, and then mixing with HEK293 cells; the mass ratio of the recombinant expression vector to the PEI transfection reagent is 1:2-1:5.
[0012] Furthermore, the HEK293 cell density is 1.8×10 6 -2.2×10 6 cells / mL, cell viability greater than 95%; Each 1×10 6 HEK293 cells correspond to 0.5 ug of recombinant expression vector.
[0013] Furthermore, the in vitro culture conditions of the recombinant cells are: 37°C, 5% CO2, 90-120 rpm for 4-7 days.
[0014] Further, affinity chromatography is used to separate and purify the recombinantly expressed growth differentiation factor-15 from the culture supernatant, comprising: Centrifuge at 12000 rpm or above for at least 30 min to collect the cell culture supernatant; The supernatant was filtered and added to an affinity chromatography column pre-equilibrated with an equilibrium solution, and then gradient eluted with equilibrium solutions containing 0 mM, 20 mM, 250 mM and 500 mM imidazole in sequence, and the protein eluate was collected to obtain growth differentiation factor-15.
[0015] In a second aspect, the present invention provides a growth differentiation factor-15, which is prepared according to any of the above-mentioned methods for preparing a growth differentiation factor-15.
[0016] Compared with the prior art, the present invention has the following beneficial effects: (1) The present invention utilizes the HEK293 expression system to obtain a large amount of growth differentiation factor-15 in a short period of time, with a purity of more than 95% and an expression level of up to 190 mg / L.
[0017] (2) Compared with the growth differentiation factor-15 prepared using the Escherichia coli expression system, the growth differentiation factor-15 prepared using the HEK293 expression system of the present invention exhibits better titer when used as an immunogen for antibody preparation. In addition, during the expression process of the HEK293 expression system, the post-translational modification process in the cell is more comprehensive, effectively ensuring the correct glycosylation, phosphorylation and other modifications of the growth differentiation factor-15 protein, thereby ensuring the biological activity and stability of the growth differentiation factor-15.
[0018] (3) The growth differentiation factor-15 expression and purification process is simple to operate, has good reproducibility, and can be put into mass production. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 It is a map of the expression vector pcDNA3.1 provided in the embodiment of the present invention; Figure 2 A schematic diagram of nucleic acids constructed according to an embodiment of the present invention; Figure 3 This is an SDS-PAGE image of the purified growth differentiation factor-15 in the embodiment of the present invention; Figure 4 This is an SDS-PAGE image of growth differentiation factor-15 after dialysis in an embodiment of the present invention; Figure 5 This is a comparison chart of the activities of growth differentiation factor-15 expressed by Escherichia coli and growth differentiation factor-15 expressed by HEK293 cells binding to antibodies respectively detected by ELISA in the embodiments of the present invention; Figure 6 The SDS-PAGE diagram of the anti-GDF-15 monoclonal antibody prepared in the example of the present invention. DETAILED DESCRIPTION
[0020] The present invention provides a method for preparing growth differentiation factor-15, which specifically utilizes HEK293 cells to efficiently express growth differentiation factor-15, wherein the HEK293 cells are human embryonic kidney 293 cells (human embryonic kidney 293, referred to as HEK293); the amino acid sequence of growth differentiation factor-15 is shown in SEQ ID NO:1.
[0021] A method for preparing growth differentiation factor-15 comprises the following steps: (1) Construction of a growth differentiation factor-15 recombinant expression vector; (2) Transfection of HEK293 cells with the growth differentiation factor-15 recombinant expression vector; (3) Growth differentiation factor-15 recombinant protein was expressed in HEK293 cells; (4) Harvesting recombinantly expressed growth differentiation factor-15 from the culture cell supernatant.
[0022] The present invention is further described below in conjunction with the accompanying drawings. The following examples are only used to more clearly illustrate the technical solution of the present invention, and cannot be used to limit the scope of protection of the present invention. Unless otherwise specified, the examples are all carried out according to conventional experimental conditions, with reference to the experimental operation steps of the "Molecular Experiment Guide (Fourth Edition)", or according to the conditions recommended by the manufacturer's instructions.
[0023] Example 1: Construction of recombinant expression vector.
[0024] The nucleic acid encoding the growth differentiation factor-15 was synthesized by General Biotechnology (Anhui) Co., Ltd., and the nucleic acid was optimized to obtain a nucleic acid with a nucleotide sequence as shown in SEQ ID NO:5, and an amino acid sequence as shown in SEQ ID NO:4. Figure 2 Shown is a schematic diagram of nucleic acid construction.
[0025] The optimization of nucleic acid includes: adding restriction endonuclease NheⅠ restriction site and Kozak sequence at the 5' end; adding termination codon and restriction endonuclease HindⅢ restriction site at the 3' end.
[0026] The stop codon is TGA, TAA or TAG.
[0027] The present invention introduces a signal peptide at the N-terminus of growth differentiation factor-15 to help the recombinantly expressed growth differentiation factor-15 to be successfully secreted into the cell culture supernatant, wherein the amino acid sequence of the signal peptide is shown in SEQ ID NO:2.
[0028] Furthermore, the present invention introduces a poly His tag at the N-terminus of growth differentiation factor-15 for protein separation and purification, and its amino acid sequence is shown in SEQ ID NO: 3. Specifically, the poly His tag is located between the N-terminus of growth differentiation factor-15 and the signal peptide.
[0029] The amino acid sequence comprising the NheⅠ restriction site, Kozak sequence, signal peptide, poly His tag, growth differentiation factor-15, stop codon and HindⅢ restriction site is shown in SEQ ID NO:4, and the corresponding nucleotide sequence is shown in SEQ ID NO:5.
[0030] The nucleic acid is double-digested with restriction endonucleases NheⅠ and HindⅢ, and then subjected to agarose gel electrophoresis, and the gel is cut to recover the target fragment.
[0031] The target fragments were connected to pcDNA3.1(+) which was also double-digested with restriction endonucleases NheⅠ and HindⅢ. Figure 1 Shown is the map of pcDNA3.1. The pcDNA3.1(+) used was purchased from Invitrogen, catalog number: V790-20. The constructed recombinant expression vector was named pCDNA3.1-6His-GDF-15.
[0032] The invention comprises constructing a gene encoding a leader peptide into a mammalian cell expression vector for guiding the secretory expression of the N protein.
[0033] The promoter used in the eukaryotic expression vector can be a CMV promoter (Cytomegalovirus Immediate Early Promoter), a SV40 promoter (Simian Virus 40 Promoter) or a T7 promoter.
[0034] E. coli DH5α was transformed with pCDNA3.1-6His-GDF-15 and cultured at 37°C for 16 h before picking a single colony for plasmid extraction. The extracted plasmid was double-digested with restriction endonucleases NheⅠ and HindⅢ and then identified by agarose gel electrophoresis. The positive clones were sent to General Biotechnology (Anhui) Co., Ltd. for sequencing, and the clones with correct sequencing were selected for plasmid amplification and extraction. The extracted plasmid was sterile filtered and stored at -20°C for later use.
[0035] Example 2: The recombinant expression vector was used to transfect HEK293 cells and express growth differentiation factor-15.
[0036] In this example, the constructed recombinant expression vector pCDNA3.1-6His-GDF-15 was transfected into HEK293 cells using PEI transfection reagent to perform recombinant expression of growth differentiation factor-15. The mass ratio of the recombinant expression vector to the PEI transfection reagent was 1:2-1:5. The cells were counted on the day of transfection and the cell density was adjusted to 2×10 6cells / mL, the viability was above 95%, and the transfected cell volume was 30mL.
[0037] The amount of each component in the transfection complex was calculated based on the cell density. The corresponding relationship between the number of recombinant expression vectors and cells was: per 1×10 6 HEK293 cells correspond to 0.5 ug of recombinant expression vector; Preferably, the corresponding relationship between the PEI transfection dose and the plasmid is: the mass of PEI is 4 times the mass of the plasmid.
[0038] Prepare the transfection complex according to the component dosage calculated above: add 30 uL of the recombinant expression vector with a concentration of 1 mg / mL to KG 293 CM1 culture medium to 900 uL (liquid A), add 120 uL of PEI transfection reagent with a concentration of 1 mg / mL to KG 293 CM1 culture medium to 900 uL (liquid B), mix them separately, slowly add liquid B to liquid A, mix and let stand at room temperature for 10 minutes, then slowly add the transfection mixture dropwise to 30 mL HEK293 cells, culture at 37°C, 5% CO2, 90-120 rpm for 4-7 days, and collect the supernatant.
[0039] Specifically, in this example, the transfection mixture was slowly added dropwise to 30 mL of HEK293 cells and cultured at 37° C., 5% CO 2 , and 100 rpm for 6 days.
[0040] The cell culture medium used was KG 293 CM1 culture medium, purchased from Jiangsu KeyGen Biotech Co., Ltd., catalog number: KGL4201-500.
[0041] Example 3: Isolation and purification of growth differentiation factor-15.
[0042] The recombinant protein was separated and purified using a His-tag affinity chromatography column. The specific steps are as follows: 12000rpm and above, centrifuge for at least 30 min to collect the cell culture supernatant; the embodiment of the present invention uses 12000rpm centrifugation for 30 min to collect the above cell culture supernatant; The supernatant was filtered and added to an affinity chromatography column that had been pre-equilibrated with an equilibrium solution (50 mM Tris, 500 mM NaCl, pH 8.0). Gradient elution was then performed with equilibrium solutions containing 0 mM, 20 mM, 250 mM and 500 mM imidazole, with an elution volume of 5-10 CV for each concentration. The protein eluate was collected, which was growth differentiation factor-15.
[0043] like Figure 3The figure shows the SDS-PAGE diagram of purified growth differentiation factor-15. Lane 1 is the cell culture supernatant; Lane 2 is the flow-through; Lane 3 is eluted with 20mM imidazole; Lane 4 is eluted with 250mM imidazole-1; Lane 5 is eluted with 250mM imidazole-2; Lane 6 is eluted with 250mM imidazole-3; Lane 7 is eluted with 250mM imidazole-4; Lane 8 is eluted with 500mM imidazole; M represents protein marker. According to the SDS-PAGE results, the purity of growth differentiation factor-15 eluted under 20mM and 250mM imidazole conditions is as high as more than 95%. The proteins are mixed and dialyzed. The molecular weight cutoff of the dialysis bag used is 3.5KDa. The dialysis is carried out overnight in a refrigerator at 4°C. The dialysate used is: 50mM Tris, 150mM NaCl, pH8.0.
[0044] The dialyzed samples were subjected to SDS-PAGE detection. Figure 4 As shown, lane 1 is 2 μg of dialyzed GDF-15 under reducing conditions; lane 2 is 2 μg of dialyzed GDF-15 under non-reducing conditions; M represents protein marker. SDS-PAGE results show that the size of the purified protein band is 15KDa, which is consistent with the theoretical molecular weight of the protein, and the purity is as high as 95%, and the expression level is as high as 190mg / L.
[0045] Example 4: Comparison of antibody binding activity between HEK293 cell-expressed growth differentiation factor-15 and Escherichia coli-expressed growth differentiation factor-15.
[0046] In this example, an enzyme-linked immunosorbent assay (ELISA) was used to compare the binding activity of the growth differentiation factor-15 expressed by HEK293 of the present invention and the growth differentiation factor-15 expressed by Escherichia coli with the antibody. Specifically, the following steps were included: (1) Coating: Coat a 96-well plate with 0.2 μg / well (2 μg / ml, 100 μL / well) of growth differentiation factor-15 antibody (Jinan Protein Biotechnology Co., Ltd., catalog number: DA100) at 4°C overnight. The coating buffer used for antibody dilution is PBS, pH 7.4.
[0047] (2) Washing: After coating, discard the liquid in the well plate and wash the plate three times with PBST at 350 μL / well using a plate washer. After the last wash, pat the plate dry. (3) Blocking: Use 1% BSA (prepared in PBST) at 200uL / well at 37°C for 2h; (4) Washing: After blocking, discard the liquid in the well plate and wash the plate three times with PBST at 350 μL / well using a plate washer. After the last wash, pat the ELISA plate dry. (5) Adding antigen: Add 100 μL of 0.56-100000 ng / mL growth differentiation factor-15 prepared in Example 3 or growth differentiation factor-15 expressed by E. coli to each well and incubate at 37°C for 1 hour. The sample was diluted in advance with dilution buffer PBS, pH 7.4.
[0048] (6) Washing: After the above incubation, discard the liquid in the well plate and wash the plate three times with PBST at 350 μL / well using a plate washer. After the last wash, pat the ELISA plate dry. (7) Add colorimetric antibody: dilute anti-His-HRP antibody with PBST at a ratio of 1:10,000, add 100 μL / well to the washed plate, and incubate at 37°C for 1 h. (8) Washing: After the above incubation, discard the liquid in the well plate and wash the plate three times with PBST at 350 μL / well using a plate washer. After the last wash, pat the ELISA plate dry. (9) Color development: Add TMB reagent at 100 μL / well, protect from light, and incubate at room temperature for 15 min; (10) Termination of reaction: Add 1 M H2SO4 at 50 μL / well to terminate the reaction; (11) Reading: Read the OD value at 450 nm, and then OD450-OD Blank is the final OD value. The well corresponding to ODBlank is the value measured in step (5) without adding sample but only adding an equal volume of dilution buffer, which serves as a blank control.
[0049] Test results such as Figure 5 As shown, from Figure 5 It can be seen that the EC50 value of the binding of the growth differentiation factor-15 expressed by Escherichia coli to the antibody is 484.2 ng / ml, while the EC50 value of the binding of the growth differentiation factor-15 expressed by the HEK293 cells of the present invention to the antibody is 51.1 ng / ml, indicating that the binding activity of the growth differentiation factor-15 expressed by HEK293 cells to the anti-growth differentiation factor-15 antibody is higher.
[0050] Example 5: Preparation of anti-GDF-15 monoclonal antibody.
[0051] In this example, the growth differentiation factor-15 separated and purified in Example 3 was used to prepare anti-growth differentiation factor-15 monoclonal antibody.
[0052] (1) Animal immunization: 50 μg of growth differentiation factor-15 was fully mixed with an equal volume of Freund's complete adjuvant and emulsified, and then injected subcutaneously at multiple points on the back of Balb / c mice (0.2 mL / point) for the first immunization. Three weeks later, 50 μg of growth differentiation factor-15 was fully mixed with an equal volume of Freund's incomplete adjuvant and emulsified, and then injected subcutaneously at multiple points on the back of Balb / c mice (0.2 mL / point) for the second immunization. Three weeks later, 50 μg of growth differentiation factor-15 was dissolved in physiological saline and injected intraperitoneally for the third immunization. One week later, blood was collected to detect the immunization effect. Based on the immunization effect, 50 μg of growth differentiation factor-15 was injected into the mouse tail vein two weeks later for booster immunization. The spleen was removed three days later and spleen cells were isolated.
[0053] (2) Cell fusion and hybridoma selection: Myeloma cells SP2 / 0 and spleen cells were mixed at a ratio of 1:5. After centrifugation, 1 mL of fusion agent PEG4000 was added to the cell pellet for fusion. The cells were transferred to a 96-well plate and screened with a selective medium containing 1% HAT. The medium was replaced by half every 2 days. After 10-14 days, the cell culture supernatant was taken for ELISA screening. For hybridoma cells that grew well, a limiting dilution operation was performed to allow each cell to grow in isolation and form a monoclonal cell line. The monoclonal cells were expanded and cultured and then cryopreserved for seed preservation.
[0054] (3) Expansion of monoclonal cells: Remove monoclonal cells from the existing culture dish, centrifuge to remove the supernatant, use new serum-free culture medium to suspend the cells, adjust the cell density based on the cell count results, add them to the pre-prepared rotary culture flask, and collect the monoclonal cell supernatant after culturing for an appropriate number of days.
[0055] (4) Purification of monoclonal antibodies: The monoclonal cell culture supernatant was collected by centrifugation at 12,000 rpm for 30 min, filtered and added to the rProtein A Beads gravity column that had been pre-equilibrated with equilibration solution (20 mM PB, 150 mM NaCl, pH 7.4). After the sample had completely flowed through the column, it was rinsed with equilibration solution for 5-10 CV, and then eluted with elution solution (0.1 M glycine, pH 3.0) and collected in separate tubes. The collected protein eluate was supplemented with 0.1 times the elution volume of neutralizing solution (1 M Tris, pH 9.0) and subjected to SDS-PAGE analysis. Figure 6 As shown, lane 1 is 3 μg bovine serum albumin, under reducing conditions; lane 2 is 3 μg anti-growth differentiation factor-15 monoclonal antibody, under reducing conditions; M represents protein Marker.
[0056] The results of SDS-PAGE showed that the molecular weight of the heavy chain of the anti-growth differentiation factor-15 monoclonal antibody was about 80-90KDa, and the molecular weight of the light chain was about 20-25KDa, which was consistent with the theoretical molecular weight of the anti-growth differentiation factor-15 monoclonal antibody, and the purity was as high as over 95%.
[0057] The method for preparing growth differentiation factor-15 by using HEK293 cells of the present invention has a complete growth differentiation factor-15 expression and purification process with simple operation and good repeatability, and the obtained growth differentiation factor-15 has good function and stability, providing researchers with a protein with better functionality and higher stability.
[0058] SEQ ID NO:1 ARNGDHCPLPGRCCRLHTVRASLEDLGWADWVLSPREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDLLAKDCHCI SEQ ID NO:2 MGWSCIILFLVATATGVHS SEQ ID NO:3 HHHHHH SEQ ID NO:4 MGWSCIILFLVATATGVHSHHHHHHARNGDHCPLGPGRCCRLHTVRASLEDLGWADWVLSPREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYNPMVLIQKTDTGVSLQTYDDLLAKDCHCI SEQ ID NO:5 atgggctggagctgtatcatcctgttcctggtggccaccgccaccggcgtgcactctcaccaccaccaccatcacgccagaaatggcgaccactgccctctg ggccctggcagatgctgccggctgcacaccgtgagggcctccctggaggacctgggctgggctgattgggtgctgtccccagaggtgcaggtgaccatgt gcatcggcgcctgcccttcccagttcagagccgccaacatgcacgcccagatcaagaccagcctgcacagactgaagcccgataccgtgcccgccccttgctg tgtgcccgcttcctacaaccctatggtgctgatccagaagaccgacaccggcgtgtccctgcaaacctacgacgatctgctggccaaggactgccactgcatc
[0059] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the technical principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing growth differentiation factor-15, characterized in that: include: A nucleic acid for preparing growth differentiation factor-15 is constructed, the nucleotide sequence of which is shown in SEQ ID NO:5; Connecting the nucleic acid to an expression vector by enzyme digestion to obtain a recombinant expression vector; HEK293 cells were transfected with the recombinant expression vector to obtain recombinant cells; The recombinant cells are cultured in vitro, the culture supernatant is collected by centrifugation, and then separated and purified to obtain the recombinantly expressed growth differentiation factor-15.
2. The method according to claim 1, characterized in that The amino acid sequence encoded by the nucleic acid is shown in SEQ ID NO:
4.
3. The method according to claim 1, characterized in that The nucleic acid is connected to the expression vector through two restriction sites, NheⅠ and HindⅢ, to obtain a recombinant expression vector.
4. The method according to claim 1, characterized in that: The promoter used in the expression vector is any one of CMV promoter, SV40 promoter or T7 promoter.
5. The method according to claim 1, characterized in that: The expression vector is pcDNA3.1(+).
6. The method according to claim 1, characterized in that Transfecting HEK293 cells with the recombinant expression vector includes: mixing the recombinant expression vector with a PEI transfection reagent, and then mixing with the HEK293 cells; the mass ratio of the recombinant expression vector to the PEI transfection reagent is 1:2-1:
5.
7. The method according to claim 1, characterized in that The density of HEK293 cells was 1.8-2.2×10 6 cells / mL, cell viability greater than 95%; Each 1×10 6 HEK293 cells correspond to 0.5 ug of recombinant expression vector.
8. The method according to claim 1, characterized in that The in vitro culture conditions of the recombinant cells are: 37°C, 5% CO2, 90-120 rpm for 4-7 days.
9. The method according to claim 1, characterized in that: The recombinantly expressed growth differentiation factor-15 was separated and purified from the culture supernatant by affinity chromatography, including: Centrifuge at 12000 rpm or above for at least 30 min to collect the cell culture supernatant; The supernatant was filtered and added to an affinity chromatography column pre-equilibrated with an equilibrium solution, and then gradient eluted with equilibrium solutions containing 0 mM, 20 mM, 250 mM and 500 mM imidazole in sequence, and the protein eluate was collected to obtain growth differentiation factor-15.
10. A growth differentiation factor-15, characterized in that It is obtained according to the method for preparing a growth differentiation factor-15 according to any one of claims 1-9.
Citation Information
Patent Citations
Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
CN108367053A
HSA-GDF-15 fusion polypeptide and use thereof.
WO2015198199A1
